Selected research
Industry Research
Cellular Tumor Antigen p53 Industry Research Report 2026
Market perspective
The global Cellular Tumor Antigen p53 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cellular Tumor Antigen p53 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cellular Tumor Antigen p53 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cellular Tumor Antigen p53 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cellular Tumor Antigen p53 include Z53 Therapeutics, LLC, Tara Immuno-Oncology Therapeutics LLC, Stemline Therapeutics, Inc., SK Biopharmaceuticals Co., Ltd., Shenzen SiBiono GeneTech Co., Ltd., Quark Pharmaceuticals, Inc., PCI Biotech Holding ASA, OSE Pharma SA and ORCA Therapeutics B.V., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cellular Tumor Antigen p53 market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cellular Tumor Antigen p53 Market by Company
Z53 Therapeutics, LLC
Tara Immuno-Oncology Therapeutics LLC
Stemline Therapeutics, Inc.
SK Biopharmaceuticals Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Quark Pharmaceuticals, Inc.
PCI Biotech Holding ASA
OSE Pharma SA
ORCA Therapeutics B.V.
Eleos Inc.
Critical Outcome Technologies Inc.
Cellceutix Corporation
Aprea AB
American Gene Technologies International Inc.
Advaxis, Inc.
Cellular Tumor Antigen p53 Segment by Type
APR-246
ATRN-502
COTI-2
D-12PGJ3
MJ-05
MX-225
Cenersen Sodium
Others
Cellular Tumor Antigen p53 Segment by Application
Prostate Cancer
Brain Cancer
Ovarian Cancer
Others
Cellular Tumor Antigen p53 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cellular Tumor Antigen p53 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cellular Tumor Antigen p53 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cellular Tumor Antigen p53.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cellular Tumor Antigen p53 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cellular Tumor Antigen p53 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cellular Tumor Antigen p53 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- APR-246
- ATRN-502
- COTI-2
- D-12PGJ3
- MJ-05
- MX-225
- Cenersen Sodium
- Others
Applications
- Prostate Cancer
- Brain Cancer
- Ovarian Cancer
- Others
Companies covered
- Z53 Therapeutics, LLC
- Tara Immuno-Oncology Therapeutics LLC
- Stemline Therapeutics, Inc.
- SK Biopharmaceuticals Co., Ltd.
- Shenzen SiBiono GeneTech Co., Ltd.
- Quark Pharmaceuticals, Inc.
- PCI Biotech Holding ASA
- OSE Pharma SA
- ORCA Therapeutics B.V.
- Eleos Inc.
- Critical Outcome Technologies Inc.
- Cellceutix Corporation
- Aprea AB
- American Gene Technologies International Inc.
- Advaxis, Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cellular Tumor Antigen p53 Market Size (2021-2032)
- 2.2.2 Global Cellular Tumor Antigen p53 Sales (2021-2032)
- 2.2.3 Global Cellular Tumor Antigen p53 Market Average Price (2021-2032)
- 2.3 Cellular Tumor Antigen p53 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 APR-246
- 2.3.3 ATRN-502
- 2.3.4 COTI-2
- 2.3.5 D-12PGJ3
- 2.3.6 MJ-05
- 2.3.7 MX-225
- 2.3.8 Cenersen Sodium
- 2.3.9 Others
- 2.4 Cellular Tumor Antigen p53 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Prostate Cancer
- 2.4.3 Brain Cancer
- 2.4.4 Ovarian Cancer
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cellular Tumor Antigen p53 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cellular Tumor Antigen p53 Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Cellular Tumor Antigen p53 Revenue of Manufacturers (2021-2026)
- 3.4 Global Cellular Tumor Antigen p53 Average Price by Manufacturers (2021-2026)
- 3.5 Global Cellular Tumor Antigen p53 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cellular Tumor Antigen p53, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cellular Tumor Antigen p53, Product Type & Application
- 3.8 Global Manufacturers of Cellular Tumor Antigen p53, Established Date
- 3.9 Global Cellular Tumor Antigen p53 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Z53 Therapeutics, LLC
- 4.1.1 Z53 Therapeutics, LLC Company Information
- 4.1.2 Z53 Therapeutics, LLC Business Overview
- 4.1.3 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Z53 Therapeutics, LLC Cellular Tumor Antigen p53 Product Portfolio
- 4.1.5 Z53 Therapeutics, LLC Recent Developments
- 4.2 Tara Immuno-Oncology Therapeutics LLC
- 4.2.1 Tara Immuno-Oncology Therapeutics LLC Company Information
- 4.2.2 Tara Immuno-Oncology Therapeutics LLC Business Overview
- 4.2.3 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tara Immuno-Oncology Therapeutics LLC Cellular Tumor Antigen p53 Product Portfolio
- 4.2.5 Tara Immuno-Oncology Therapeutics LLC Recent Developments
- 4.3 Stemline Therapeutics, Inc.
- 4.3.1 Stemline Therapeutics, Inc. Company Information
- 4.3.2 Stemline Therapeutics, Inc. Business Overview
- 4.3.3 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Stemline Therapeutics, Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.3.5 Stemline Therapeutics, Inc. Recent Developments
- 4.4 SK Biopharmaceuticals Co., Ltd.
- 4.4.1 SK Biopharmaceuticals Co., Ltd. Company Information
- 4.4.2 SK Biopharmaceuticals Co., Ltd. Business Overview
- 4.4.3 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SK Biopharmaceuticals Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
- 4.4.5 SK Biopharmaceuticals Co., Ltd. Recent Developments
- 4.5 Shenzen SiBiono GeneTech Co., Ltd.
- 4.5.1 Shenzen SiBiono GeneTech Co., Ltd. Company Information
- 4.5.2 Shenzen SiBiono GeneTech Co., Ltd. Business Overview
- 4.5.3 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Shenzen SiBiono GeneTech Co., Ltd. Cellular Tumor Antigen p53 Product Portfolio
- 4.5.5 Shenzen SiBiono GeneTech Co., Ltd. Recent Developments
- 4.6 Quark Pharmaceuticals, Inc.
- 4.6.1 Quark Pharmaceuticals, Inc. Company Information
- 4.6.2 Quark Pharmaceuticals, Inc. Business Overview
- 4.6.3 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Quark Pharmaceuticals, Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.6.5 Quark Pharmaceuticals, Inc. Recent Developments
- 4.7 PCI Biotech Holding ASA
- 4.7.1 PCI Biotech Holding ASA Company Information
- 4.7.2 PCI Biotech Holding ASA Business Overview
- 4.7.3 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PCI Biotech Holding ASA Cellular Tumor Antigen p53 Product Portfolio
- 4.7.5 PCI Biotech Holding ASA Recent Developments
- 4.8 OSE Pharma SA
- 4.8.1 OSE Pharma SA Company Information
- 4.8.2 OSE Pharma SA Business Overview
- 4.8.3 OSE Pharma SA Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 OSE Pharma SA Cellular Tumor Antigen p53 Product Portfolio
- 4.8.5 OSE Pharma SA Recent Developments
- 4.9 ORCA Therapeutics B.V.
- 4.9.1 ORCA Therapeutics B.V. Company Information
- 4.9.2 ORCA Therapeutics B.V. Business Overview
- 4.9.3 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 ORCA Therapeutics B.V. Cellular Tumor Antigen p53 Product Portfolio
- 4.9.5 ORCA Therapeutics B.V. Recent Developments
- 4.10 Eleos Inc.
- 4.10.1 Eleos Inc. Company Information
- 4.10.2 Eleos Inc. Business Overview
- 4.10.3 Eleos Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Eleos Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.10.5 Eleos Inc. Recent Developments
- 4.11 Critical Outcome Technologies Inc.
- 4.11.1 Critical Outcome Technologies Inc. Company Information
- 4.11.2 Critical Outcome Technologies Inc. Business Overview
- 4.11.3 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Critical Outcome Technologies Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.11.5 Critical Outcome Technologies Inc. Recent Developments
- 4.12 Cellceutix Corporation
- 4.12.1 Cellceutix Corporation Company Information
- 4.12.2 Cellceutix Corporation Business Overview
- 4.12.3 Cellceutix Corporation Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Cellceutix Corporation Cellular Tumor Antigen p53 Product Portfolio
- 4.12.5 Cellceutix Corporation Recent Developments
- 4.13 Aprea AB
- 4.13.1 Aprea AB Company Information
- 4.13.2 Aprea AB Business Overview
- 4.13.3 Aprea AB Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Aprea AB Cellular Tumor Antigen p53 Product Portfolio
- 4.13.5 Aprea AB Recent Developments
- 4.14 American Gene Technologies International Inc.
- 4.14.1 American Gene Technologies International Inc. Company Information
- 4.14.2 American Gene Technologies International Inc. Business Overview
- 4.14.3 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 American Gene Technologies International Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.14.5 American Gene Technologies International Inc. Recent Developments
- 4.15 Advaxis, Inc.
- 4.15.1 Advaxis, Inc. Company Information
- 4.15.2 Advaxis, Inc. Business Overview
- 4.15.3 Advaxis, Inc. Cellular Tumor Antigen p53 Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Advaxis, Inc. Cellular Tumor Antigen p53 Product Portfolio
- 4.15.5 Advaxis, Inc. Recent Developments
5 Global Cellular Tumor Antigen p53 Market Scenario by Region
- 5.1 Global Cellular Tumor Antigen p53 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cellular Tumor Antigen p53 Sales by Region: 2021-2032
- 5.2.1 Global Cellular Tumor Antigen p53 Sales by Region: 2021-2026
- 5.2.2 Global Cellular Tumor Antigen p53 Sales by Region: 2027-2032
- 5.3 Global Cellular Tumor Antigen p53 Revenue by Region: 2021-2032
- 5.3.1 Global Cellular Tumor Antigen p53 Revenue by Region: 2021-2026
- 5.3.2 Global Cellular Tumor Antigen p53 Revenue by Region: 2027-2032
- 5.4 North America Cellular Tumor Antigen p53 Market Facts & Figures by Country
- 5.4.1 North America Cellular Tumor Antigen p53 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cellular Tumor Antigen p53 Sales by Country (2021-2032)
- 5.4.3 North America Cellular Tumor Antigen p53 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cellular Tumor Antigen p53 Market Facts & Figures by Country
- 5.5.1 Europe Cellular Tumor Antigen p53 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cellular Tumor Antigen p53 Sales by Country (2021-2032)
- 5.5.3 Europe Cellular Tumor Antigen p53 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cellular Tumor Antigen p53 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cellular Tumor Antigen p53 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cellular Tumor Antigen p53 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cellular Tumor Antigen p53 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cellular Tumor Antigen p53 Market Facts & Figures by Country
- 5.7.1 South America Cellular Tumor Antigen p53 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cellular Tumor Antigen p53 Sales by Country (2021-2032)
- 5.7.3 South America Cellular Tumor Antigen p53 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cellular Tumor Antigen p53 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cellular Tumor Antigen p53 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cellular Tumor Antigen p53 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cellular Tumor Antigen p53 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cellular Tumor Antigen p53 Sales by Type (2021-2032)
- 6.1.1 Global Cellular Tumor Antigen p53 Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Cellular Tumor Antigen p53 Sales Market Share by Type (2021-2032)
- 6.2 Global Cellular Tumor Antigen p53 Revenue by Type (2021-2032)
- 6.2.1 Global Cellular Tumor Antigen p53 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cellular Tumor Antigen p53 Revenue Market Share by Type (2021-2032)
- 6.3 Global Cellular Tumor Antigen p53 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cellular Tumor Antigen p53 Sales by Application (2021-2032)
- 7.1.1 Global Cellular Tumor Antigen p53 Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Cellular Tumor Antigen p53 Sales Market Share by Application (2021-2032)
- 7.2 Global Cellular Tumor Antigen p53 Revenue by Application (2021-2032)
- 7.2.1 Global Cellular Tumor Antigen p53 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cellular Tumor Antigen p53 Revenue Market Share by Application (2021-2032)
- 7.3 Global Cellular Tumor Antigen p53 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cellular Tumor Antigen p53 Value Chain Analysis
- 8.1.1 Cellular Tumor Antigen p53 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cellular Tumor Antigen p53 Production Mode & Process
- 8.2 Cellular Tumor Antigen p53 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cellular Tumor Antigen p53 Distributors
- 8.2.3 Cellular Tumor Antigen p53 Customers
9 Global Cellular Tumor Antigen p53 Analyzing Market Dynamics
- 9.1 Cellular Tumor Antigen p53 Industry Trends
- 9.2 Cellular Tumor Antigen p53 Industry Drivers
- 9.3 Cellular Tumor Antigen p53 Industry Opportunities and Challenges
- 9.4 Cellular Tumor Antigen p53 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst